Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 14Lymphoid 6Genitourinary 5Other hematologic neoplasm 3Gastrointestinal 2Thoracic 1Other solid neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Thrombocytosis 1Thrombocytopenia 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Follicular 1Anemia 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × siltuximab × Classical hematology × Clear all
NCT02805868 2016-10-24

Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Northwestern University

Phase EARLY_PHASE1 Withdrawn
Classical hematologyLymphoidMyeloid

Anemia, Lymphoma, Follicular, Polycythemia Vera, Thrombocytopenia, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡